Document:

Exhibit 10.69

 

  

		[***]	Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

 

AMENDMENT NO. 2

TO RESEARCH COLLABORATION AGREEMENT

 

This Amendment No. 2 to the Research Collaboration
Agreement (this Amendment) is dated as of December 3, 2012 (the Effective Date), between:

 

		(1)	INTERNATIONAL AIDS VACCINE INITIATIVE, a not-for-profit corporation with its new principal
offices located at 125 Broad Street, Floor 9, New York, NY 10004 (IAVI); and

 

		(2)	THERACLONE SCIENCES, INC. a biotechnology company with its principal offices located at
1124 Columbia Street, Suite 300, Seattle, WA 98104 (Theraclone).

 

IAVI and Theraclone are each a Party
and together the Parties.

 

RECITALS

 

WHEREAS, IAVI and Theraclone entered into
a Research Collaboration Agreement dated July 1, 2009, and Amendment No.1 dated November 24, 2010 (the Agreement); and

 

WHEREAS, the Parties wish to amend the
Total Fixed Price of the Agreement and the Scope of Work in this Amendment No. 2.

 

IT IS AGREED AS FOLLOWS:

 

		1.	Definitions

 

Unless otherwise provided herein,
all defined terms used in this Amendment No. 2 will have the same meaning as in the Agreement.

 

		2.	Amendment of Section 3 (Fixed Price and Payment)

 

Sections 3 is amended to include
the following modified or new language:

 

		“(a)	The total fixed price for the performance of activities covered in the Scope
of Work by Theraclone through Amendment No.1 is [***] (the Total Fixed Price).

 

(f)Theraclone acknowledges
that IAVI has fully paid for the completion of the original and Amendment No. 1 Scope of Work which included a 6th Protocol G donor
deliverables which have not been delivered because of the absence of the an acceptable donor sample to initiate the work.

 

 

 

* Confidential Treatment Requested.

    	1

    	 

    

 

(g)The Parties agree to further
modify the Agreement under this Amendment No. 2 to address a new Scope of Work as defined in the revised Attachment 1.

 

(h) The Fixed Price Amount for
the revised Scope of Work for this Amendment No, 2 is [***]. Payment of the non-refundable,
non-creditable amount of [***] will be made upon activation of the first donor sample
as contemplated in Attachment 1 to this Amendment.

 

		3.	Amendment of Compliance

 

Section 7 of the Agreement are
hereby deleted and replaced as follows:

 

“(a)Theraclone agrees
to comply with all laws, statutes, rules, regulations, and guidelines promulgated by any governmental agency, instrumentality,
authority, or regulatory body having jurisdiction over any matters relating to the Discovery Program, including those related to
studies involving micro-organisms, animals, or human subjects.

 

(b)Theraclone acknowledges
that it is familiar with the U.S. Executive Orders and laws that prohibit the provision of resources and support to individuals
and organizations associated with terrorism and the terrorist related lists promulgated by the U.S. Government. Theraclone will
use reasonable efforts to ensure that it does not support or promote violence, terrorist activity or related training, or money
laundering.

 

(c)IAVI funded a portion
of the original and Amendment No.1 Scope of Work with monies from the United States Agency for International Development (USAID).
Therefore, the original and a portion of Amendment No.1 and a portion of Amendment No, 2 Scopes of Work will be administered in
accordance with the USAID Standard Provisions incorporated as Attachment II to the Agreement, with the exception of the following
provisions which do not apply to this Agreement as currently executed: 2, 3, 4, 12, 13, 14, 19, 20, 21, 24, 26 and 29. In the event
the scope/nature of this Agreement changes, this exception may be modified as deemed required by the Parties. Effective September
13, 2011 IAVI will fund the Project Activities from the United States Agency for International Development (USAID) Cooperative
Agreement No. AID-OAA-A-11-00020 and therefore, this Agreement will be administered in accordance with the USAID Standard Provisions
incorporated as Attachment III to this Agreement, with the exception of the following provisions which do not apply to this Agreement
as currently executed: 2, 3, 4, 12, 13, 14, 19, 20, 21, 24, 26 and 29. In the event the scope/nature of this Agreement changes,
this exception may be modified as deemed required by the Parties.”

 

(d)IAVI anticipates that
it will fund a portion of the Scope of Work for, the Protocol C Donor Sample SOW in Attachment 1, for Amendment No. 2 with monies
from a National Institute of Health (NIH) grant. Therefore, the Scope of Work for Amendment No. 2 will be administered in
accordance with the NIH grant standard provisions, including reporting of inventions, incorporated as Attachment IV with the exception
of the following provision which to not apply to this agreement as currently executed: 3,4,5,6, 16, 27.

 

 

*Confidential Treatment Requested

    	2

    	 

    

 

(e)In the event that IAVI
utilizes monies originating from restricted sources other than USAID or an NIH grant to fund the Scope of Work, IAVI shall notify
Theraclone and provide Theraclone with copies of any rules, regulations, and grant requirements applicable to the Scope of Work
funded with such monies. Restricted monies compliance provisions will be incorporated as an amendment to this Agreement’s
terms and conditions only after IAVI and Theraclone discuss them in good faith and mutually agree upon the use of such funds for
the Scope of Work. IAVI agrees that it shall inform Theraelone of any such restrictions that present the potential for material
breach of this Agreement as soon as possible.

 

(f)For the avoidance of doubt,
due to restrictions contained in the informed consents used to obtain the new biological specimens provided to Theraclone under
this Agreement, those biological specimens can only be used for the field of HIV, i.e., prophylactic and/or therapeutic HIV/AIDS
vaccines, related diagnostic tools and HIV/AIDS treatment. In compliance with US Department of Health and Human Services/Office
of Human Research Protection guidance, IAVI will not under any circumstances provide Theraclone personal identifying information
or the key to decipher the code for any biological specimen to reveal the identity of the donor.

 

(g)If Theraelone uses subcontractors
to assist in the completion of the Scope of Work, Theraclone is responsible for ensuring that any such subcontractor complies with
the terms and conditions of this Agreement and the Scope of Work.”

 

		4.	Amendment of Expiration or Termination

 

Section 8 of the Agreement is
hereby deleted and replaced as follows:

 

“(a)IAVI may terminate
this Agreement immediately after providing Theraclone with sixty (60) days prior written notice if (i) IAVI is not reasonably satisfied
with Theraclone’s diligence in performing the Scope of Work, or (ii) Theraclone fails to comply with any material term or
condition of this Agreement, provided that such failure in performance or non-compliance is not cured within such sixty (60) day
period. IAVI also reserves the right to withhold funds or terminate this Agreement if significant changes in scientific staffing
at Theraclone occur that IAVI believes may jeopardize the Discovery Program.

 

(b)Theraclone may terminate
this Agreement immediately after providing IAVI with sixty (60) days prior written notice of such failure to comply with any material
term or condition of this Agreement, provided that such non-compliance is not cured within such sixty (60) day period.

 

(c)Upon expiration or termination
of this Agreement, and upon (i) IAVI’s request, Theraclone shall either destroy or return to IAVI all IAVI Materials, and
(ii) Theraclone’s request, IAVI shall either destroy or return to Theraclone all Theraclone Materials (for clarification,
Theraclone Materials do not include Program Inventions and Program Deliverables (as set forth in the Scope of Work)).

 

    	3

    	 

    

 

(d)Upon the termination of
the Agreement, Sections 6, and 8(c) through 17 shall survive any termination.

 

		5.	Amendment of the Scope of Work

 

The Scope of Work as amended
in Amendment No. 1 shall be amended to include Attachment 1 which is attached to this Amendment.

 

		6.	Full Force and Effect

 

Except as specifically modified
or amended in this Amendment, the Agreement will remain in full force and effect. No oral promise, covenant or representation of
any character or nature has been made to induce either Party to enter into this Amendment. No provision of this Amendment may be
modified or amended except expressly in a writing signed by both Parties nor will any term be waived except expressly in a writing
signed by the party charged therewith.

 

		7.	Counterparts

 

This Amendment may be executed
in one or more counterparts, each of which together will be deemed original but all of which together will constitute one and the
same document. A photocopy of the original signature of an authorized representative of a party will have the same validity as
an original signature for the purpose of this Agreement.

 

		8.	Governing Law

 

This Amendment will be governed
by and construed in accordance with the laws of the State of New York, without giving effect to principles of conflicts of laws.

 

    	4

    	 

    

IN WITNESS WHEREOF, the Parties hereto
have caused this Amendment to be duly executed by their authorized representatives.

 

 

	International AIDS Vaccine Initiative	 	Theraclone Sciences, Inc.
	 	 	 
	 	 	 
	By 	/s/ Wayne Koff	 	By 	/s/ Russ Hawkinson
	Name:Wayne Koff	 	Name:Russ Hawkinson
	Title:Senior Vice President & CSO	 	Title:CFO
	Date:12-3-12	 	Date:12/11/12
	 	 	 
	 	 	 

 

 

 

    	5

    	 

    

ATTACHMENT 1 – Amendment No.
2

 

SCOPE OF WORK

 

[***]

 

 

*Confidential Treatment
Requested

    	6

    	 

    

ATTACHMENT III

Supplementary Provisions:

Standard USAID Requirements

 

Contractor shall comply with the standard
USAID requirements specified in this Appendix. The term “Contractor” shall also mean “Recipient” or “Grantee”
and the term “Agreement” shall also mean “Contract”, “Award” or “Grant” for the
purposes of these requirements.

 

	1.	Applicability of 22 CFR 226	21.	Condoms
	2.	Reimbursable Costs	22.	Prohibition on the Promotion or Advocacy of the Legalization or Practice of Prostitution or Sex Trafficking
	3.	Indirect Costs	23.	Equal Protection of the Laws for Faith-Based and Community Organizations
	4.	Accounting Systems and Records	24.	Voluntary Population Planning Activities
	5.	Payment Advances and Refunds	25.	Participant Training
	6.	Debarment	26.	Reporting of Foreign Taxes
	7.	Probity	27.	Drug Free Workplace
	8.	Nonliability and Disclaimers	28.	USAID Disability Policy
	9.	Procurement and Eligibility Rules of Goods and Services	29.	Foreign Government Delegations to International Conferences
	10.	Capital Expenditures	30.	Marking under USAID Funded Assistance
	11.	Travel and Transportation	31.	Universal Identifier
	12.	Human Subjects Research	32.	Reporting Sub-Awards and Executive Compensation
	13.	Animal Welfare	33.	Trafficking in Persons
	14.	Worker’s Compensation Insurance	34.	Prohibition of Assistance to Drug Traffickers
	15.	Nondiscrimination	35.	Byrd Anti-Lobbying Amendment
	16.	Real Property	 	 
	17.	Clean Air/Water	 	 
	18.	Publications and Media Releases	 	 
	19.	Investment Promotion	 	 
	20.	Organizations Eligible for Assistance	 	 

 

The following are the principal standard federal
requirements applicable to the performance of both parties’ responsibilities under this Agreement (in addition and without
prejudice to the other provisions of this Agreement):

 

		(1)	Applicability of 22 CFR Part 226. This provision is only applicable to agreements and subagreements awarded to U.S.
organizations. All provisions of 22 CFR Part 226 are applicable to this Agreement.

 

		(2)	Reimbursable Costs. This Provision is only applicable to cost reimbursement contracts. To be reimbursable under
this Agreement, costs must comply with the applicable cost principles. For educational institutions, use OMB Circular A-21; for
all other non-profit organizations, use OMB Circular A-122; and for profit making firms, use Federal Acquisition Regulation 31.2
(see below). Requirements include the following, without limitation: direct costs must be necessary and incurred specifically for
the Services; verifiable from the books and records of Contractor, as applicable, and supported by source documentation; allocable
to this Agreement; reasonable in nature and amount; and allowable (i.e. conform to the provisions and limitations of this Agreement).
To facilitate monitoring of charges under this Agreement, once each year, IAVI may provide Contractor with a USAID compliance form
which Contractor agrees to fill out completely and accurately and return promptly to IAVI for review and consultation as appropriate.

 

    	7

    	 

    

 

		(3)	Indirect Costs. This Provision is only applicable to cost reimbursement contracts. Unless predetermined indirect
cost rates are included in the approved budget for this Agreement (or each Task Order, when applicable), funding from USAID will
only be used for reimbursable direct costs.

 

		(4)	Accounting Systems, Records and Audits. This Provision is only applicable to cost reimbursement contracts. Contractor
shall maintain books, records, documents and other evidence in accordance with generally accepted and recognized accounting procedures.
Contractor shall preserve and make available its accounting records and documents for examination and audit by IAVI, USAID and
the Comptroller General of the United States, or any of their duly authorized representatives: (a) until the expiration of three
years from the termination of this Agreement; (b) for such longer period, if any, as is required to complete an audit to resolve
all questions concerning expenditures unless written approval has been obtained from USAID to dispose of the records; and (c) if
any litigation, claim, or audit is started before the expiration of the three year period, the records shall be retained until
all litigation, claims, or audit findings involving the records have been resolved. Contractor agrees to make available any further
information requested by either IAVI or USAID with respect to any questions arising as a result of the aforementioned audit. U.S.
organizations are also subject to the audit requirements of 22 CFR 226.26 (Non-Federal Audits). Non-U.S. organizations may be subject
to annual audit in accordance with the “Guidelines for Financial Audits Contracted by Foreign Recipients” issued by
the USAID Inspector General.

 

		(5)	Payment Advances and Refunds. If Contractor receives advance payments under this Agreement, Contractor shall maintain
advances in interest bearing accounts unless: 1) Contractor receives less than $120,000 in U.S. Government awards per year; or
2) the best interest bearing account would not be expected to earn more than $250 in interest each year; or 3) the bank would require
an unreasonable average or minimum balance so as to make it impractical to do so. Interest earned in excess of $250 per year must
be refunded to IAVI. In addition, funds advanced to Contractor but not expended by the end of this Agreement or not expended in
accordance with the terms of this Agreement must be refunded to IAVI.

 

		(6)	Debarment. Contractor certifies that neither it nor its principals is presently excluded or disqualified or proposed
for exclusion or disqualification from participation in this Agreement by any U.S. Federal department or agency (see the U.S. Government’s
Excluded Parties List at http://epls.arnet.gov). Furthermore, Contractor agrees that it will not knowingly enter into a
subcontract or subaward with a disqualified or excluded party on this list. Contractor agrees to notify IAVI immediately upon learning
that it or any of its principals: 1) are presently excluded or disqualified from covered transactions by any Federal department
or agency; 2) have been indicted or otherwise criminally or civilly charged, convicted of or had a civil judgment rendered against
them for commission of any of the acts listed in the USAID Standard Provision entitled “Debarment, Suspension, and other
Responsibility Matters”; or 3) have had one or more public transactions (with local, State or the Federal governments) terminated
for cause or default within the preceding three years. Contractor shall include this provision in any subcontracts or subawards
under this Agreement.

 

    	8

    	 

    

 

		(7)	Probity. Contractor represents and warrants that (i) to the best of its knowledge and belief, no IAVI employee, officer,
or agent, or member of his/her immediate family, his or her partner, or an organization which is about to employ any of the foregoing,
has a financial interest in Contractor; and (ii) no officer, employee or agent of IAVI has solicited or accepted gratuities, favors,
or anything of monetary value from Contractor.

 

		(b)	U.S. Executive Orders and U.S. law prohibit transactions with, and the provision of resources and
support to, individuals and organizations associated with terrorism. It is the legal responsibility of Contractor to ensure compliance
with these Executive Orders and laws in the conduct of its own activities. Contractor is required to obtain the updated lists at
the time of procurement of goods or services. The updated lists are available at: http://www.treas.gov/offices/enforcement/ofac/sdn/t11sdn.pdf
and http://www.un.org/sc/committees/1267/consolist.shtml. This provision must be included in all contracts, subcontracts
or subawards awarded hereunder.

 

		(8)	Nonliability and Disclaimers. Contractor agrees that USAID will not assume liability for third party claims for damages
arising out of this Agreement and that Contractor will have no relationship with USAID solely because of this Agreement.

 

		(9)	Procurement and Eligibility Rules of Goods and Services. (a) Procurements of goods and services pursuant to this Agreement
shall be conducted in accordance with sound commercial practices and the USAID Standard Provisions “USAID Eligibility Rules
for Goods and Services (April 1998)” and shall be supported by original invoices or other appropriate supporting documentation.
Furthermore, procurement by U.S. organizations should be in accordance with the procurement procedures outlined in 22 CFR 226.44,
and procurement by non-U.S. organizations should be in accordance with the Standard Provisions for Non-U.S. Organizations entitled
“Procurement of Goods and Services (October 1998)”. The text of these policies is available on USAID’s website
(see below).

 

(b) Goods on USAID’s list
of ineligible items (military equipment, surveillance equipment, equipment to support police or law enforcement activities, abortion
equipment, luxury goods, gambling equipment, and weather modification equipment) may not be financed. Goods on USAID’s list
of restricted items (agricultural equipment, pesticides, fertilizers, U.S. government-owned excess property, used equipment, pharmaceuticals,
including HIV Test kits, motor vehicles and motor bikes) may only be financed with IAVI’s prior written approval.

 

(c) Other Goods and services may
be procured from any country except the following Foreign Policy Restricted Countries: Cuba, Iran, Iraq, Laos, North Korea, or
Syria. Goods may not be procured from firms on the U.S. government’s Excluded Parties List (see “http://epls.arnet.gov”).
For purposes of the preceding sentence, “procured from” includes supplier nationality (for goods and services) and
the source and origin of the goods.

 

    	9

    	 

    

 

		(10)	Capital Expenditures.

 

(a) Unless indicated otherwise in
the schedule of this Agreement, title to all equipment purchased with funds provided hereunder shall belong to IAVI.

 

(b) Contractor must obtain IAVI’s
prior written approval before: (i) purchasing capital equipment or (ii) incurring costs for renovations or other material improvements
to land, buildings or equipment.

 

		(11)	Travel and Transportation. This provision is applicable when international travel is authorized under this Agreement.
Unless included in the approved budget for this Agreement, no funds may be expended for international travel without IAVI’s
written approval. Expenditures of funds provided under this Agreement (i) for transportation of goods or travel of personnel overseas
shall be subject to the USAID Standard Provision, “International Air Travel and Transportation (JUNE 1999),” and (ii)
for shipments of goods by sea shall be subject to the USAID Standard Provision, “Ocean Shipment of Goods (JUNE 1999).”
U.S. flag carriers must be used to the extent service by such carriers is available. The text of these provisions is available
on USAID’s website (see below). This provision will be included in all subawards and contracts hereunder which require international
travel and transportation.

 

		(12)	Human Subjects Research. This provision is applicable when human subjects research is conducted pursuant to this
Agreement. Contractor agrees to comply with USAID policies, to the extent applicable, including without limitation the Common
Federal Policy for the Protection of Human Subjects (implemented by USAID at 22 CFR Part 225); the “Procedures for Protection
of Human Subjects in Research Supported by USAID”; and the USAID Standard Provision entitled “Protection of the Individual
as a Research Subject (APRIL 1998).” The texts of these policies are available on USAID’s website (see below.)

 

		(13)	Animal Welfare. This provision is applicable when research involving laboratory animals is conducted pursuant to
this Agreement. Contractor agrees to work with IAVI to ensure compliance with USAID policies to the extent applicable, as referenced
in the USAID Standard Provision entitled “Care of Laboratory Animals (MARCH 2004)”. The text of this policy is available
on USAID’s website (see below).

 

		(14)	Worker’s Compensation Insurance. The provision is applicable to U.S. based contractors who will perform work
hereunder outside the United States. Pursuant to 22 CFR Part 226, Appendix A, Contractor agrees to provide worker’s compensation
insurance to all persons employed outside the U.S. who are U.S. citizens or residents. Contractor agrees to provide insurance required
by applicable law to all persons employed outside the U.S. who are not U.S. citizens or residents

 

		(15)	Nondiscrimination. This provision is applicable when work under this Agreement will be performed in the United States
or when employees are recruited in the United States. No U.S. citizen or legal resident of the United States will be excluded
from participation in, be denied the benefits of, or be otherwise subjected to discrimination under any activity funded under this
Agreement on the basis of race, color, national origin, age, handicap or sex. Contractor will comply with E.O. 11246, “Equal
Employment Opportunity,” as amended by E.O. 11375, “Amending Executive Order 11246 Relating to Equal Employment Opportunity,”
and as supplemented by regulations at 41 CFR Chapter 60, “Office of Federal Contract Compliance Programs, Equal Employment
Opportunity, Department of Labor,” to the extent required by the foregoing.

 

    	10

    	 

    

 

		(16)	Real Property. Funding may not be used under this Agreement to construct, alter, repair or improve real property without
IAVI’s advance written approval, which [approval] may be subject to additional USAID requirements.

 

		(17)	Clean Air/Water. This provision is applicable to contracts in excess of $100,000 to be performed in the United States.
Contractor agrees to comply with all applicable standards, orders or regulations pursuant to the Clean Air Act (42 U.S.C. 7401
et seq.) and the Federal Water Pollution Control Act as amended (33 U.S.C. 1251 et seq.) Violations are to be reported to IAVI.

 

		(18)	Publications and Media Releases. (a) Contractor shall provide to IAVI, for submission to USAID, one hard copy and one
electronic copy in PDF form, if available, of all published works developed under this Agreement. Each document submitted should
contain essential bibliographic elements such as 1) descriptive title; 2) author(s) name; 3) date of publication; 4) and a statement
that this publication was funded in whole or in part by the International AIDS Vaccine Initiative under Cooperative Agreement No.
AID-OAA-A-11-00020 awarded by the U.S. Agency for International Development (Office of Health/AIDS, Bureau of Global Health, S.O.
4100201).

 

(b) In the event funds provided
under this Agreement are used to fund the cost of publishing, any related profits or royalties realized by Contractor (up to the
amount of these publishing costs) should be credited back to this Agreement.

 

(c) Except as otherwise provided
elsewhere in this Agreement, the author or Contractor is free to copyright any books, publications or copyrightable materials development
under this Agreement; however USAID reserves a royalty-free nonexclusive and revocable right to reproduce, publish, or otherwise
use, and to authorize others to use, the work for U.S. government purposes.

 

(d) Any “public communications”,
as defined in 22 CFR 226.2, funded under this Agreement in which the content has not been approved by USAID, must contain the following
disclaimer:

 

“This study/report/audio/visual/other information/media
project is made possible by the generous support of the American people through the United States Agency for International Development
(USAID). The contents are the responsibility of [insert Contractor’s name] and do not necessarily reflect the views of USAID
or the United States Government”.

 

    	11

    	 

    

 

		(19)	Investment Promotion. Except as may be specifically set forth in this Agreement or as IAVI may otherwise approve in
advance, no funds or other support provided under this Agreement may be used by Contractor for an activity that involves investment
promotion in a foreign country. The Contractor must ensure that its employees and subrecipients and contractors providing investment
promotion services are made aware of these restrictions and include this clause in all subagreements and contracts.

 

		(20)	Organizations Eligible for Assistance. If Contractor is otherwise eligible to receive funds under this Agreement to
prevent, treat, or monitor HIV/AIDS, Contractor shall not be required to endorse or utilize a multisectoral approach to combatting
HIV/AIDS or to endorse, utilize, or participate in a prevention method or treatment program to which Contractor has a religious
or moral objection. The Contractor shall include this provision in any subcontracts or subawards under this Agreement.

 

		(21)	Condoms. If information is provided under this Agreement about the use of condoms, the information shall be medically
accurate and shall include the public health benefits and failure rates of such use and shall be consistent with USAID’s
fact sheet entitled “USAID: HIV/STI Prevention and Condoms”. This fact sheet may be accessed at: http://www.usaid.gov/our
work/global health/aids/TechAreas/prevention/condomfactshe et.html.”

 

		(22)	Prohibition on the Promotion or Advocacy of the Legalization or Practice of Prostitution or Sex Trafficking. None of
the funds made available under this Agreement may be used by Contractor to promote or advocate the legalization or practice of
prostitution or sex trafficking. The funds made available under this Agreement may be used by Contractor to provide palliative
care, treatment, or post-exposure pharmaceutical prophylaxis, and necessary pharmaceuticals and commodities, including test kits,
condoms, and, when proven effective, microbicides, if applicable under this Agreement. For the purposes of this provision, “sex
trafficking” means the recruitment, harboring, transportation, provision, or obtaining of a person for the purpose of a commercial
sex act; “commercial sex act” means any sex act on account of which anything of value is given to or received by any
person and; “prostitution” means procuring or providing any commercial sex act and the “practice of prostitution”
has the same meaning. The Contractor shall include this provision in any subcontracts or subawards under this Agreement.

 

		(23)	Equal Protection of the Laws for Faith-Based and Community Organizations. (a) In providing services supported by this
Agreement or in its outreach activities related to these services, Contractor may not discriminate against any beneficiary or potential
beneficiary on the basis of religion, a religious belief, a refusal to hold a religious belief, or a refusal to actively participate
in a religious practice.

 

(b) If Contractor engages in
inherently religious activities, these activities must occur at a different time and/or location from any programs or services
funded by this Agreement and participation by beneficiaries in any such inherently religious activities must be voluntary. The
Contractor must not engage in any inherently religious activities, such as worship, religious instruction or proselytization as
part of the programs or services funded under this Agreement.

 

    	12

    	 

    

 

(c) In awarding subagreements
or contracts under this Agreement, Contractor should not discriminate against a faith-based organization in selecting qualified
organizations or impose additional requirements when awarding to a religious organization.

 

(d) When Contractor is a religious
organization, Contractor:

 

		(1)	Retains its independence and may continue to carry out its mission, including the definition, practice,
and expression of its religious beliefs, provided that it does not use funds from this Agreement to support any inherently religious
activities, such as worship, religious instruction, or proselytization.

 

		(2)	Retains its authority over its internal governance and may retain religious terms in its organization’s
name, select its board members on a religious basis, and include religious references in its organization’s mission statements
and other governing documents.

 

		(3)	Retains its exemption from the Federal prohibition on employment discrimination on the basis of religion,
set forth in Sec. 702(a) of the Civil Rights Act of 1964, 42 U.S.C. 2000e-1.

 

		(4)	May use space in its facilities, without removing religious art, icons, scriptures, or other religious
symbols.

 

		(24)	Voluntary Population Planning Activities — Mandatory Requirements. (a) No funds under this Agreement may be used
to pay for the performance of involuntary sterilization as a method of family planning or to coerce or provide any financial incentive
to any individual to practice sterilization.

 

(b) No funds under this Agreement
made be used to finance, support or be attributed to any activities whatsoever related to the performance of abortion as a method
of family planning, including paying incentives to coerce or motive individuals to have abortions. The term “motivate”
as it relates to family planning assistance shall not be construed to prohibit the provision, consistent with local law, of information
or counseling about all pregnancy options.

 

(c) No funds under this Agreement
may be used for biomedical research which relates in whole or in part to the methods or performance of abortions or involuntary
sterilizations as a means of family planning. This does not preclude epidemiological or descriptive research to assess the incidence,
extent or consequences of abortions.

 

(d) When giving guidance and information
regarding family planning the Contractor shall provide a broad range of family planning methods and services available in the country
in which the activity is conducted or shall provide information to such individuals regarding where such methods and services may
be obtained. The Contractor shall notify IAVI immediately if it learns about an alleged violation of the terms of this Provision
24(d).

 

		(25)	Participant Training. This provision is applicable to this Agreement if training will be provided to any non-U.S.
individual outside of that individual’s home country. Participant training under this Agreement shall comply with the
policies established in USAID ADS Chapter 253.

 

    	13

    	 

    

 

		(26)	Reporting of Foreign Taxes. Quarterly financial reports or other requests for reimbursement in accordance with the payment
terms of this Agreement should include the amount of any value added tax (VAT) and custom duties paid to the foreign government
of the country receiving assistance hereunder on commodity purchase transactions valued at $500 or more financed under this Agreement
as well as any reimbursements of such taxes that may be received during the period of this Agreement. “Commodity” means
any material, article, supply, goods or equipment.

 

		(27)	Drug Free Workplace. Within 30 days after either the effective date of this Agreement, if awarded after September 13,
2011 or of the effective date of the amendment incorporating this provision if this Agreement was awarded prior to September 13,
2011, Contractor agrees to publish a drug-free workplace statement and provide a copy to each employee who will be engaged in performance
of this Agreement. The statement must be in accordance with the USAID Standard Provision entitled “Drug-Free Workplace (JAN
2004)”. Contractor agrees to both immediately notify IAVI if an employee working hereunder is convicted of a drug violation
in the workplace and to either terminate the employee or take other appropriate action in accordance with the above- referenced
Standard Provision.

 

		(28)	USAID Disability Policy. Contractor shall not discriminate against people with disabilities in the implementation of
the program funded by this Agreement and shall make every effort to comply with the objectives of the USAID Disability Policy to
the extent that it can do so within the scope of the program. The full text of the policy can be found at http://www.usaid.gov/about/disability/DISABPOL.FIN.html.

 

		(29)	Foreign Government Delegations to International Conferences. Funds in this Agreement may not be used to finance any
travel costs or conferences fees for any member of a foreign government’s delegation to an international conference sponsored
by a public international organization, except as provided in USAID ADS Mandatory Reference “Guidance on Funding Foreign
Government Delegations to International Conferences” or as approved by USAID.

 

		(30)	Marking under USAID Funded Assistance. As a condition of receipt of this Agreement,. Contractor must mark all overseas
programs, projects, activities, public communications and commodities in accordance with the attached IAVI Marking Plan. In doing
so, marking with either the IAVI logo or the USAID logo (as stipulated) should be of a size and prominence equivalent to or greater
than the logos of Contractor, Contractor’s other donors, or third parties.

 

		(31)	Universal Identifier. This Provision is only applicable to sub-awards. If applicable, Contractor will be requested
to provide this information prior to the award of an agreement. The Contractor is required to have a Data Universal Numbering
System (DUNS) Number prior to the award of an Agreement by IAVI. A Data Universal Numbering System (DUNS) number means the nine-digit
number established and assigned by Dun and Bradstreet, Inc. (D&B) to uniquely identify business entities. A DUNS number may
be obtained from D&B by telephone (currently 866-705-5711) or the Internet (currently at http://fedgov.dnb.com/webform).
IAVI is not authorized to enter into an Agreement with any Contractor that has not provided IAVI with the Contractor’s DUNS
Number.

 

    	14

    	 

    

 

		(32)	Reporting Sub-Awards and Executive Compensation. This Provision is only applicable to sub-awards. If applicable,
Contractor will be requested to provide this information prior to the award of an agreement. This provision is only applicable
to agreements equal to [***] or more. IAVI must report agreements in excess of [***]
on the Federal Funding Accountability and Transparency Act (FFATA) Sub-Award Reporting System (FSRS). The information that must
be reported for each agreement includes information regarding the Contractor’s five most highly compensated executives. As
a result the Contractor must report the names, title and compensation of its five most highly compensated executives to IAVI, if
(i) in the Contractor’s preceding fiscal year the Contractor received: (a) 80 percent or more of its annual gross revenues
from Federal procurement contracts (and subcontracts) and Federal financial assistance subject to the Transparency Act, as defined
at 2 CFR 170.320 (and subawards); and (b) [***] or more in annual gross revenues
from Federal procurement contracts (and subcontracts), and Federal financial assistance subject to the Transparency Act (and subawards);
and (ii) the public does not have access to information about the compensation of the executives through periodic reports filed
under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a),78o(d)) or section 6104 of the Internal Revenue
Code of 1986. (To determine if the public has access to the compensation information, see the U.S. Security and Exchange Commission
total compensation filings at http://www.sec.gov/answers/execomp.htm). The Contractor will be requested to provide this
information to IAVI by completing a FFATA Sub-Award Reporting Certification Form.

 

		(33)	Trafficking in Persons. The Contractor and the Contractor’s employees, subcontractors and the subcontractor’s
employees may not: (a) Engage in severe forms of trafficking in persons during the period of time that the Agreement is in effect;
(b) Procure a commercial sex act during the period of time that the Agreement is in effect; and (c) Use forced labor in the performance
of the Agreement. IAVI shall have the right to unilaterally terminate this Agreement if the Contractor, the Contractor’s
employees, subcontractors or subcontractor’s employees is determined to have violated any of the prohibitions of this Provision.
The Contractor must inform IAVI immediately of any information the Contractor receives from any source alleging a violation of
any prohibitions of this Provision. The Contractor shall include this provision in any subcontracts or subawards under this Agreement.

 

Definitions: (a) “Employee”
means either: (i) An individual employed by you or a subrecipient who is engaged in the performance of the Agreement; or (ii) Another
person engaged in the performance of the Agreement and not compensated by you including, but not limited to, a volunteer or individual
whose services are contributed by a third party as an in-kind contribution toward cost sharing or matching requirements; (b) “Forced
labor” means labor obtained by any of the following methods: the recruitment, harboring, transportation, provision, or obtaining
of a person for labor or services, through the use of force, fraud, or coercion for the purpose of subjection to involuntary servitude,
peonage, debt bondage, or slavery; (c) “Severe forms of trafficking in persons,’” “commercial sex act,”
and “coercion” have the meanings given at section 103 of the TVPA, as amended (22 U.S.C. 7102).

 

 

*Confidential Treatment
Requested

 

    	15

    	 

    

 

		(34)	Prohibition of Assistance to Drug Traffickers. IAVI reserves the right to terminate this Agreement or take other appropriate
measures if the Contractor or a key individual of the Contractor is found to have been convicted of a narcotic offense or to have
been engaged in drug trafficking as defied in 22 CFR 140.

 

		(35)	Byrd Anti-Lobbying Amendment. Pursuant to 22 CFR Part 227, Contractor agrees to: (a) sign and submit to IAVI (i) upon
signing of this Agreement, the required certification that it has not used and will not use federal appropriated funds to influence
various government officials in making certain federal awards, using the “Certification Regarding Lobbying” form, and
(ii) the “Disclosure of Lobbying Activities Form”, if it uses or has agreed to use funds other than federal appropriated
funds for this purpose; (b) sign and submit to IAVI at the end of each calendar quarter the Standard Form LLL, Disclosure of Lobbying
Activities Form, if (i) it uses or has agreed to use funds other than federal appropriated funds and/or (ii) an event occurs that
materially affects (as defined in 22 CFR Part 227) the accuracy of any information contained in any Disclosure Form previously
submitted by the Contractor to IAVI. This provision must be included in all contracts, subcontracts or sub-awards exceeding $100,000
awarded hereunder.

 

The text of the Standard Provisions and
other regulations that are referenced above is available at the following websites. IAVI will provide a copy upon request.

 

22 CFR Part 226 - http://ecfr.gpoaccess.gov/cgi/t/text/text-

idx?c=ecfr&tpl=/ecfrbrowse/Title22/22cfr226_main_02.tpl

OMB Circular A-122 - http ://www.whitehouse.gov/omb/circulars/a122/a122_2004.html

OMB Circular A-21 - http://www.whitehouse.gov/omb/circulars/a021/a21_2004.html

FAR Part 31.2 - https://www.acquisition.gov/far/html/Subpart%2031_2.html

USAID Standard Provisions for U.S. Organizations
- http://www.usaid.gov/policy/ads/300/303maa.pdf

USAID Standard Provisions for non-U.S. Organizations
- http://www.usaid.gov/policy/ads/300/303mab.pdf

 

    	16

    	 

    

IAVI Marking Plan

under USAID Cooperative Agreement AID-OAA-A-11-00020

 

As an international organization, IAVI’s
continued success in accelerating the development of promising HIV vaccine candidates relies upon long-term engagement with our
diverse portfolio of contributors and other stakeholders. This fact is reflected in our Marking Plan. Under this Plan, IAVI had
developed a multi-donor logo which acknowledges all of IAVI’s governmental and largest private sector donors. This logo will
be applied universally, both domestically and outside the U.S., to mark items such as physical infrastructure, workshops, and program
communications; however, the USAID-logo sticker by itself will be used to mark equipment procured entirely with USAID funds. For
example, when appropriate, items would be marked as follows:

 

		·	Publications and other public communications marked with IAVI multi-donor logo in a visible location
such as the front or back cover

 

		·	Invitation letterhead, report or cover marked with IAVI multi-donor logo in a visible location such
as in the body text or footnoted

 

		·	Equipment marked with a USAID logo sticker in a visible location

 

		·	Infrastructure marked with a IAVI multi-donor plaque in a visible location

 

Marking with either the IAVI logo or the USAID
logo (as stipulated above) should be of a size and prominence equivalent to or greater than the logos of the contractor/recipient,
other donors, or other third parties. The Marking Plan Table which follows indicates the items and activities to be marked and
those which are exempt from marking.

 

The USA ID logo stickers (for equipment) can
be either obtained from IAVI or ordered directly from vendors listed on the USAID website (http://www.usaid.gov/branding/suppliers.html).
Three versions of the logo below are available to allow for flexibility of usage. Upon request, an electronic file of all three
versions of the IAVI multi-donor logo will be sent by IAVI to the contractor/recipient.

 

 

 

    	 

    	 

    

IAVI MARKING TABLE

 

	ACTIVITY	TO BE MARKED	NOT TO BE MARKED (EXEMPT)*
	External Publications	Informational, educational and communication materials for use by staff, partners and other stakeholders on AIDS vaccines and related topics (includes leaflets & brochures)	Reports and publications done in partnership with governments
	Research working papers, policy briefs, and discussion papers	 
	 	 	 
	Tools and Operational Documents	Tool
    kit for needs assessment/program planning for community involvement	 
	Community advisory board(s) guidance documents	 
	 	 	 
	Reports	Reports
of select social science research projects on issues relevant to clinical research in developing countries or reports from needs
assessment and monitoring and evaluation efforts	Reports on programs involving governmental policies and programs
	 	 	 
	Workshops, technical meetings, training programs, seminars, consultations	Invitation
letters, informational handouts, briefs, reports, and meeting signage	Invitation
    letters, informational handouts, briefs, reports, and meeting signage for Policy Makers Workshops covering national policy
    issues
	 	Meetings and trainings implemented in partnership with the Government of India
	 	 	 
	Human Immunology Laboratory (Imperial College; trial sites and laboratories in Africa and India; biotechnology firms and pharmaceuticals outside the U.S.)	Buildings/facilities	Internal
Documents (e.g. Good Clinical Laboratory Practice guidelines, standard operating procedures guidelines, audits, validation study
reports, clinical trial study reports, etc.)
	Laboratory and office equipment unless item is too small or marking would impair functionality	Consumables and laboratory supplies such as scissors, forceps, test tubes, vaccine vials, pipettes
	Shipping containers packed with equipment or supplies to the Africa or India IAVI sites unless marking would jeopardize the integrity of the contents	Shipping clinical samples from site to London or Johannesburg core labs

 

* If IAVI determines that these items/activities
are no longer exempt, IAVI will notify the subawardee or contractor in writing that these items/activities should also be marked
with the IAVI multi-donor logo (or the USAID logo for equipment).

 

    	18/29	 

    	 

    

ATTACHMENT IV

 

NIH Standard Provisions

 

Theraclone shall comply with the standard
NIH requirements specified in this Attachment. Throughout these provisions, Theraclone shall be defined as Subawardee.

 

		1.	General Provisions

 

This Agreement is subject to the
terms and conditions incorporated either directly or by reference in the following:

 

		a.	45 CFR Part 74; and

 

		b.	The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

 

		2.	Prior Approval

 

As outlined in the administrative
requirements of the NIH Grants Policy Statement, NIH prior written approval may be required before IAVI makes certain budget modifications
or undertakes particular activities. As a result, Subawardee agrees to obtain written prior approval from IAVI for the following
activities and/or expenditures under this Agreement:

 

		§	Change in scope

		§	Change in key personnel

		§	Carryover of unobligated balances

		§	Deviation from Agreement terms and conditions

		§	Transfer of the Performance of Substantive Programmatic Work to a Third Party by Means of a Consortium Agreement

		§	Change in the specific aims approved at the time of award

		§	Substitution of one animal model for another

		§	Any change from the approved use of animals or human subjects

		§	Shift of the research emphasis from one disease area to another

		§	A clinical hold by FDA under a study involving an IND or an IDE

		§	Application of a new technology, e.g., changing assays from those approved to a different type of assay

		§	Significant rebudgeting, whether or not the particular expenditure(s) require prior approval. Significant rebudgeting occurs
when expenditures in a single direct cost budget category deviate (increase or decrease) from the categorical commitment level
established for the budget period by more than 25 percent of the total costs awarded. The base used for determining significant
rebudgeting excludes the effects of prior-year carryover balances but includes competing and non-competing supplements.

		§	Incurrence of research patient care costs if costs in that category were not previously approved by NTH or if a grantee desires
to rebudget additional funds beyond those approved into or rebudget funds out of the research patient care category

 

    	19/29	 

    	 

    

 

		3.	Reimbursable Costs

 

		a.	To be reimbursable under this Agreement, costs must comply with the applicable cost principles. For state, local or federally-recognized
Indian tribal governments use OMB Circular A-87; for institutions of higher education, use OMB Circular A-21; for non-profit organizations,
use OMB Circular A-122; for hospitals, use Appendix E of 45 CFR Part 74; and for profit making firms, Federal Acquisition Regulation
(FAR) at 48 CFR part 31, except that independent research and development costs are unallowable.

 

		b.	Requirements include the following, without limitation: direct costs must be necessary and incurred specifically for the Project
Activities; verifiable from the books and records of Subawardee, as applicable, and supported by source documentation; allocable
to this Agreement; reasonable in nature and amount; and allowable (i.e. conform to the provisions and limitations of this Agreement).

 

		4.	Accounting Systems, Records and Audits

 

Subawardee shall maintain books,
records, documents and other evidence in accordance with generally accepted accounting procedures. Subawardee shall preserve and
make available its accounting records and documents for examination and audit by, NIH or the Comptroller General of the United
States, or any of their duly authorized representatives: (a) until the expiration of three years from the termination of this Agreement;
(b) for such longer period, if any, as is required to complete an audit to resolve all questions concerning expenditures unless
written approval has been obtained from NTH to dispose of the records; and (c) if any litigation, claim, or audit is started before
the expiration of the three year period, the records shall be retained until all litigation, claims, or audit findings involving
the records have been resolved. Subawardee agrees to make available any further information requested by either IAVI or NIH with
respect to any questions arising as a result of the aforementioned audit. Such audit shall be at no cost to Theraclone.

 

		5.	Procurement

 

Procurements of goods and services
pursuant to this Agreement shall be conducted in accordance with sound commercial practices and 45 CFR Part 74 or 45 CFR Part 92
(as applicable) and the NIH Grants Policy Statement and shall be supported by original invoices or other appropriate supporting
documentation.

 

		6.	Equipment

 

Subawardee must obtain IAVI’s
prior written approval before: (i) purchasing equipment or (ii) incurring costs for renovations or other material improvements
to land, buildings or equipment. Title to any equipment purchased by the Subawardee under this Agreement will be, unless otherwise
agreed in writing by IAV1, held by IAVI subject to the conditions of 45 CFR Part 74.34. The Equipment will be used as determined
by the Parties under the terms of the SOW during the term of this Agreement and thereafter as determined by IAVI. Upon the termination
or expiration of this Agreement, IAVI may, at its sole discretion, grant Subawardee title to, or retain title to, any Equipment
and if IAVI does not grant Subawardee title, Subawardee will promptly return such Equipment (at IAVI’s expense) to IAVI.
Subawardee will be responsible for the proper use and maintenance of any Equipment during the term of this Agreement.

 

    	20/29	 

    	 

    

 

		7.	Real Property

 

Funding may not be used under this
Agreement to construct, alter, repair or improve real property without IAVI’s advance written approval. This approval is
subject to 45 CFR Part 74.32.

 

		8.	Publications and Media Releases

 

Subawardee will make the results
and accomplishments of the Project Activities available to the research community and to the public at large. Subawardee shall
provide to IAVI, for submission to NIH, one hard copy and one electronic copy in PDF form, if available, of all published works
developed under this Agreement. Each publication, press release or other document that cites results from activities funded under
this Agreement must include an acknowledgment of NIH grant support and disclaimer such as “The project described was supported
by Award Number U19A1090970 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases
or the National Institutes of Health.”

 

The Subawardee is required to comply
with the NIH Public Access Policy. This includes submission to PubMed Central (AMC), upon acceptance for publication, an electronic
version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National
Institutes of Health. The author’s final peer-reviewed manuscript is defined as the final version accepted for journal publication,
and includes all modifications from the publishing peer review process. For additional information, please visit http://publicaccess.nih.gov/.

 

		9.	Copyright

 

		a.	Subawardee shall own the rights in data it generates from the Project Activities and any publications, data, or other copyrightable
works developed under this Agreement may be copyrighted without NIH approval. Subawardee hereby grants NIH a royalty-free, nonexclusive,
and irrevocable license for the Federal government to reproduce, publish, or otherwise use the material and to authorize others
to do so for Federal purposes.

 

		b.	The disposition of royalties and other income earned from a copyrighted work is addressed on the NIH website http://grants.nih.gov/grants/policy/nihgps_2003/nihgps_part8.htm
under “Administrative Requirements - Management Systems and Procedures - Program Income.”

 

    	21/29	 

    	 

    

 

		10.	Sharing of Research Data

 

Subawardee will ensure the timely
release and sharing of final research data from the Project Activities for use by other researchers. “Timely release and
sharing” is defined as no later than the acceptance for publication of the main findings from the final data set. Data intended
for broader use should be free of identifiers that would permit linkages to individual research participants and variables that
could lead to deductive disclosure of the identity of individual subjects.

 

		11.	Sharing of Unique Research Resources

 

Subawardee will share any unique
research resources developed under this Agreement in accordance with the Principles and Guidelines for Recipients of NIH Research
Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources (64 FR 72090, December 23, 1999), which is
available on the NIH website (http://www.ott.nih.gov/policy/rt_guide_final.html). Upon the request of the NIH awarding office,
Subawardee must also provide a copy of documents or a sample of any material developed under this Agreement to NIH. Subawardee
will submit unique biological information, such as DNA sequences or crystallographic coordinates, to the appropriate data banks
so that they can be made available to the broad scientific community.

 

		12.	Rights to Inventions

 

Rights to inventions made under
this Agreement shall be determined in accordance with the standard Patent Rights clauses as specified in 37 CFR Part 401. The provisions
of the Bayh-Dole Act of 1980, as implemented in 37 CFR Part 401, as amended by the Technology Transfer Commercialization Act of
2000 (P.L. 106-404) shall apply. [Need to Discuss]

 

		13.	Standards of Conduct

 

Subawardee must establish safeguards
reflected in written standards of conduct, consistent with State and local laws, to prevent employees, consultants, members of
governing bodies, and others who may be involved in Project Activities from using their positions for purposes that are, or give
the appearance of being, motivated by a desire for private financial gain for themselves or others, such as those with whom they
have family, business, or other ties, which cover, at a minimum, expected conduct in regard to financial interests, gifts, gratuities
and favors, nepotism, and such other areas as political participation and bribery. A copy of these general standards of conduct
must be made available to each of its officers, each of its employees and consultants working on the Project Activities, each member
of the governing board, if applicable, and, upon request, to IAVI and the NIH. The NIH website http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm#_Toc54600064
provides additional information.

 

    	22/29	 

    	 

    

 

		14.	Financial Conflict of Interest

 

Subawardee must promote objectivity
in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards
are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and
any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including
the Investigator’s spouse and dependent children. Subawardee must have a written administrative process to identify and manage
financial conflict of interest and must inform Investigators of this process, the Investigators’ responsibilities, as well
as provide Investigator training on this process. Prior to expenditure of the funds awarded under this Agreement, the Subawardee
must report to IAVI the existence of a conflicting interest and within 30 days of any new conflicting interests identified after
the initial report. Subawardee must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also
apply to subgrantees, contractors, or collaborators engaged by the Awardee under this Agreement. The NIH website http://grants.nih.gov/grants/policy/coi/index.htm
provides additional information. If Subawardee or any subgrantee, contractor, or collaborator engaged by the Subawardee under this
Agreement does not have a Financial Conflict of Interest Policy in place that complies with 42 CFR Part 50, Subpart F, such Subawardee,
subgrantee, contractor, or collaborator must follow IAVI’s Research Conflict of Interest Policy for Investigators Involved
in PHS Funded Research.

 

		15.	Research Misconduct

 

The Subawardee will inquire into
and, if necessary, investigate and resolve promptly and fairly all instances of alleged or apparent research misconduct. Subawardee
agrees to comply with 42 CFR Part 50, Subpart A, “Responsibilities for PHS Awardee and Applicant Institutions for Dealing
With and Reporting Possible Misconduct in Science.” The Subawardee certifies that it has established administrative policies
as required by 42 CFR 50, Subpart A, and will comply with those policies and the requirements of the regulations. The regulations
are available from the ORI on its home page (www.ori.dhhs.gov). The Subawardee will report promptly to IAVI any incident
of alleged or apparent research misconduct that it judges as warranting investigation and must advise IAVI of any decision to initiate
an investigation. The Subawardee agrees to promptly report issues involving potential criminal violations, such as misappropriation
of funds awarded under this Agreement, to IAVI.

 

		16.	Human Subjects Research

 

		a.	Subawardee agrees to conduct human subjects research under this Agreement in compliance with 45 CFR Part 46 and the Standards
for Privacy of Individually Identifiable Health Information outlined in the NIH Grants Policy Statement.

 

		b.	Subawardee certifies that it has an appropriate OHRP-approved assurance and IRB approval of the research consistent with 45
CFR Part 46 and that it will comply with NIH prior-approval requirements related to the addition of sites not included in the approved
application. Subawardee certifies that all key personnel performing Project Activities under this Agreement have received training
in the protection of human subjects.

 

    	23/29	 

    	 

    

 

		17.	Data and Safety Monitoring

 

Subawardee agrees to comply with
NIH requirements for data and safety monitoring outlined in the NIH Grants Policy Statement.

 

		18.	Investigational New Drug Applications/Investigational Device Exceptions

 

If Project Activities under this
Agreement involve INDs, drugs approved for a different indication, or experimental combinations of drugs, Subawardee agrees to
comply with FDA’s IND regulations, FDA’s human subjects’ protection requirements, and HHS’s human subjects’
requirements. As provided in the FDA regulations, an IND or IDE also may apply to biologics or devices. The FDA regulations are
published in 21 CFR Parts 50 and 312.

 

		19.	Requirements for Inclusiveness in Research Design

 

In accordance with the NIH Grants
Policy Statement, Subawardee agrees that Project Activities under this Agreement will be as inclusive in design as possible to
extend the validity of research findings and allow for enhancement of the health status of all population groups.

 

		20.	Inclusion of Women and Minorities as Subjects in Clinical Research

 

Subawardee certifies that Project
Activities under this Agreement involving human subjects of any age will comply with the NIH Policy and Guidelines on the Inclusion
of Women and Minorities as Subjects in Clinical Research, implementing section 492B of the PHS Act. These guidelines require that
women and members of minority groups and their subpopulations be included in Project Activities under this Agreement involving
human subjects, unless a clear and compelling rationale and justification establishes, to the satisfaction of the NIH IC Director,
that inclusion is inappropriate with respect to the health of the subjects, the purpose of the research, or other circumstances.
Cost is not an acceptable reason for exclusion, except when the research would duplicate data already available from other sources.
Women of childbearing potential should not be routinely excluded from participation in clinical research. The guidelines should
be reviewed for policy concerning inclusion of these groups in all NIH-supported clinical trials. This policy applies to subjects
of all ages.

 

		21.	Inclusion of Children as Subjects in Clinical Research

 

		a.	Subawardee certifies that Project Activities under this Agreement involving human subjects will be performed in compliance
with the NIH Policy Statement and this research must include children in the research design unless there are scientific or ethical
reasons not to include them. For the purpose of addressing the NIH policy requirement for inclusion, a child is defined as an individual
under the age of 21 years.

 

    	24/29	 

    	 

    

 

		b.	The inclusion of children as subjects in Project Activities under this Agreement must comply with all applicable provisions
of pertinent Federal laws and regulations, including 45 CFR Part 46. Regulatory requirements in 45 CFR 46 Subpart D address HHS
protections for children who participate in research. These requirements must be addressed when “children” (persons
who, under the applicable law of the jurisdiction in which the research will be conducted, have not attained the legal age for
consent to treatments or procedures involved in the research) are involved as subjects in research.

 

		22.	Human Embryo Research, Cloning, and Transplantation

 

		a.	Ban on Human Embryo Research and Cloning: In accordance with NIB policy, funds awarded under this Agreement may not be used
to support human embryo research. Funds awarded under this Agreement may not be used for the creation of a human embryo for research
purposes or for research in which a human embryo is destroyed, discarded, or knowingly subjected to risk of injury or death greater
than that allowed for research on fetuses in utero under 45 CFR 46.204 and 46.207 and subsection 498(b) of the PHS Act. The term
“human embryo” includes any organism not protected as a human subject under 45 CFR 46, as of the date of enactment
of the governing appropriations act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or
more human gametes or human diploid cells.

 

		b.	In addition to the statutory restrictions on human fetal research under subsection 498 (b) of the PHS Act, by Presidential
memorandum of March 4, 1997, Subawardee is prohibited from using funds awarded under this Agreement for cloning of human beings.

 

		c.	Research on Human Fetal Tissue: Human fetal tissue is defined as tissue or cells obtained from a dead human embryo or fetus
after a spontaneous or induced abortion or stillbirth. This definition does not include established human fetal cell lines. Research
involving the transplantation of human fetal tissue must be conducted in accordance with applicable State and local laws as well
as the following NIH guidance - NIH guidance for grantees conducting research on human fetal tissue and other information on the
governing Federal statute, sections 498A and 498B of the PHS Act, 42 U.S.C. 289g-1 and 298g-2, is available on the NIH website
at http://grants.nih.gov/grants/guide/notice-files/not93-235.html.

 

		d.	Research on Transplantation of Fetal Tissue: Subawardee will make available for audit by the HHS Secretary or designee, the
physician statements and informed consents required by subsections 498A(b)(2) and (c) of the PHS Act or will ensure HHS access
to those records, if maintained by an entity other than the Subawardee. This requirement is in addition to the requirements concerning
human subjects in research.

 

    	25/29	 

    	 

    

 

		e.	In addition, FDA issued a letter on November 30, 2000, indicating that it has jurisdiction over fetal cells and tissues intended
for use in humans. FDA is requesting that investigators contact them to determine whether any planned or ongoing clinical research
would require submission of an IND application. Additional information and FDA contact information is available at http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105857.htm

 

		23.	Research Using Human Embryonic Stem Cells

 

Subawardee certifies that research
using human embryonic germ cells derived from fetal tissue will be performed in compliance with NIH guidelines outlined in the
NIH Grants Policy Statement.

 

		24.	Select Agent Research

 

Subawardee agrees to comply with
the NTH Guidelines for Research Involving DNA Molecules. The NIH Guidelines are available at http://oba.od.nih.gov/oba/rac/guidelines_02/NIH_Guidelines_Apr_02.htm.

 

		25.	Health and Safety Regulations and Guidelines

 

		a.	Subawardee is responsible for meeting Federal, State, and local health and safety standards and for establishing and implementing
necessary measures to minimize their employees’ risk of injury or illness in activities related to this Agreement. Subawardee
agrees to comply with the following regulations:

 

		b.	29 CFR 1910.1030, Bloodborne pathogens; 29 CFR 1910.1450, Occupational exposure to hazardous chemicals in laboratories; and
other applicable occupational health and safety standards issued by the Occupational Health and Safety Administration (OSHA) and
included in 29 CFR Part 1910. These regulations are available at http://www.osha.gov/comp-links.html.

 

		c.	Nuclear Regulatory Commission Standards and Regulations, pursuant to the Energy Reorganization Act of 1974 (42 U.S.C. 5801
et seq.). Copies may be obtained from the U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001.

 

		26.	Limitation on Use of Funds

 

Subawardee is prohibited from using
funds awarded under this Agreement to support the promotion of the legalization of any drug or other substance included in Schedule
I of the schedule of controlled substances established by section 202 of the Controlled Substances Act, 21 U.S.C. 812, to carry
out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug or for an abortion.

 

    	26/29	 

    	 

    

 

		27.	Animal Welfare

 

The Subawardee is responsible for
the humane care and treatment of animals in activities funded under this Agreement. Subawardees are required to establish appropriate
policies and procedures for the humane care and use of animals, based on the Office of Laboratory Animal Welfare Guide for the
Care and Use of Laboratory Animals, and to comply with the Animal Welfare Act and its implementing regulations. This includes appointing
an IACUC with specified responsibilities.

 

		28.	U.S. Executive Orders

 

U.S. Executive Orders and U.S. law
prohibit transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism.
It is the legal responsibility of Subawardee to ensure compliance with these Executive Orders and laws in the conduct of its own
activities. Subawardee is required to obtain the updated lists at the time of procurement of goods or services. The updated lists
are available at: http://www.treasury.gov/resource-center/sanctions/SDN-List/Pages/default.aspx and http://www.un.org/Docs/sc/committees/1267.
This provision must be included in all contracts, subcontracts or subawards awarded hereunder.

 

		29.	Debarment and Suspension

 

In accordance with 45 CFR Part 74.13
and 45 CFR Part 76, the Subawardee certifies that neither it nor its principals is presently excluded or disqualified or proposed
for exclusion or disqualification from participation in this Agreement by any U.S. Federal department or agency (see the General
Services Administration’s “Lists of Parties Excluded from Federal Procurement or Nonprocurement Programs” in
accordance with E.O.s 12549 and 12689, “Debarment and Suspension” at www.epls.gov). Furthermore, Subawardee
agrees that it will not knowingly enter into a subcontract or subaward with a disqualified or excluded party on this list.

 

		30.	Nondelinquency on Federal Debt

 

The Federal Debt Collection Procedures
Act of 1990 (Act), 28 U.S.C. 3201(e), provides that an organization or individual that is indebted to the United States, and has
a judgment lien filed against it, is ineligible to receive a Federal grant. The Subawardee certifies that Subawardee is not delinquent
in repaying any Federal debt, has not been judged to be in default on a Federal debt and Subawardee does not have a judgment lien
filed against it.

 

		31.	Nonliability and Disclaimers

 

Subawardee agrees that NIH will
not assume liability for third party claims for damages arising out of this Agreement and that Subawardee will have no relationship
with NIH solely because of this Agreement.

 

    	27/29	 

    	 

    

 

		32.	Equal Employment Opportunity

 

Subawardee is required to comply
with E.O. 11246, “Equal Employment Opportunity,” as amended by E.O. 11375, “Amending Executive Order 11246 Relating
to Equal Employment Opportunity,” and as supplemented by regulations at 41 CFR part 60, “Office of Federal Contract
Compliance Programs, Equal Employment Opportunity, Department of Labor. No U.S. citizen or legal resident of the United States
will be excluded from participation in, be denied the benefits of, or be otherwise subjected to discrimination under any activity
funded under this Agreement on the basis of race, color, national origin, age, handicap or sex.

 

		33.	Clean Air/Water

 

Subawardee agrees to comply with
all applicable standards, orders or regulations pursuant to the Clean Air Act (42 U.S.C. 7401 et seq.) and the Federal Water Pollution
Control Act as amended (33 U.S.C. 1251 et seq.) Violations are to be reported to 1AVI.

 

		34.	Drug Free Workplace

 

Subawardee agrees that it will provide
a drug-free workplace and will comply with the requirements of the Drug-Free Workplace Act of 1988 (Public Law 100-690, Title V,
Subtitle D, as amended) and 45 CFR Part 76. Subawardee will notify lAVI if an employee is convicted of violating a criminal drug
statute. Failure to comply with these requirements may be cause for debarment.

 

		35.	Lobbying

 

Subawardee agrees to comply with
restrictions on lobbying in accordance with 45 CFR Part 93. Subawardee certifies that it will not and has not used funds awarded
under this Agreement to pay any person or organization for influencing or attempting to influence an officer or employee of any
Federal agency, a member of Congress, officer or employee of Congress, or an employee of a member of Congress in connection with
obtaining any Federal contract, grant or any other award covered by 31 U.S.C. 1352.

 

		36.	Civil Rights

 

Subawardee certifies that it is
incompliance with and has on file with OCR an Assurance of Compliance with the statutes described below:

 

		·	Age Discrimination Act of 1975

		·	Civil Rights Act of 1964

		·	Education Amendments of 1972

		·	Rehabilitation Act of 1973

		·	Limited English Proficiency

 

    	28/29	 

    	 

    

 

For reference:

 

Code of Federal Regulations (CFR) - www.gpoaccess.gov/cfr/

OMB Circulars - www.whitehouse.gov/omb/circulars

NIH Grants Policy Statement - http://grants.nih.gov/grants/policy/policy.htm

 

    	29/29Exhibit 10.70

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (this “Agreement”)
is made and entered into this [ ] day of [ ] 2013 (the "Effective Date") by and between [ ] (the “Executive”)
and PharmAthene, Inc., a Delaware corporation (“PharmAthene” or the “Company”).

 

WITNESSETH:

 

WHEREAS, PharmAthene, Taurus Merger Sub,
Inc. (“Merger Sub”), Theraclone Sciences, Inc. (“Theraclone”) and Steven Gillis, Ph.D., as Securityholders’
Representative, have entered into an Agreement and Plan of Merger dated July 31, 2013 (the “Merger Agreement”);

 

WHEREAS, pursuant to the terms of the Merger
Agreement, the parties identified in the recital above will enter into a business combination transaction pursuant to which Theraclone
will merge with and into Merger Sub, with Theraclone being the surviving corporation and a wholly owned subsidiary of PharmAthene;

 

WHEREAS, the Executive is currently employed
by [PharmAthene] [Theraclone] and a party to an Employment Agreement with [PharmAthene] [Theraclone]
dated [ ] (the “Prior Agreement”); and

 

WHEREAS, subject to the consummation of
the transactions contemplated by the Merger Agreement, the Company desires to employ the Executive and the Executive desires to
[accept] [continue] employment with the Company subject to the terms and conditions herein agreed upon:

 

NOW, THEREFORE, in consideration of the
foregoing and of the mutual covenants and obligations hereinafter set forth, the parties hereto hereby agree as follows:

 

1.Effectiveness of Agreement. This
Agreement shall become effective upon the Effective Date.

 

2. Employment; Term. The Company
hereby agrees to employ the Executive and the Executive hereby accepts employment with the Company upon the terms and conditions
hereinafter set forth for the period commencing on the Effective Date and ending on the first anniversary of such date. The term
of this Agreement shall be automatically extended for an additional year on each anniversary of the date hereof unless written
notice of non-extension is provided by either party to the other party at least 90 days prior to such anniversary. The period of
the Executive’s employment under this Agreement, as it may be terminated or extended from time to time as provided herein
is referred to as the “Employment Period.”

 

    	 

    	 

    

 

3. Position and Duties.

 

a. Position and Duties Generally.
The Executive shall be employed by the Company in the position of [TITLE] and shall faithfully render such executive, managerial,
administrative and other services as are customarily associated with and incident to such position and as the Company may from
time to time reasonably require consistent with such position.

 

b. Other Positions. The Executive
shall hold such other positions and executive offices with the Company and/or of any of the Company’s subsidiaries or affiliates
as may from time to time be authorized by the Board of Directors of the Company (“Board”). The Executive shall not
be entitled to any compensation other than the compensation provided for herein for serving during the Employment Period in any
other office or position of the Company or any of its subsidiaries or affiliates, unless the Compensation Committee specifically
approves such additional compensation; provided, however, that the President and CEO shall review, in good faith, the Executive’s
compensation in light of these additional responsibilities, and, if deemed appropriate, recommend that the Compensation Committee
review and recommend the Board’s approval of a compensation adjustment.

 

c. Devotion
to Employment. The Executive shall be a full-time employee of the Company and shall devote the Executive’s full time,
attention and efforts during the Employment Period to the business of the Company and the duties required of the Executive in the
Executive’s position, except for vacation time taken in accordance with the Company’s vacation policy in effect from
time to time and in accordance with the terms of this Agreement and for absences due to temporary illness. During the Employment
Period, the Executive shall not be engaged in any other business activity which, in the reasonable judgment of the Board or its
designee, conflicts with the duties of the Executive hereunder, whether or not such activity is pursued for gain, profit or other
pecuniary advantage. The foregoing, however, does not prohibit the Executive from participating in civic, religious or charitable
activities, so long as such activities do not interfere with the Executive’s duties to the Company.

 

4. Compensation; Reimbursement.

 

a. Base Salary. For the Executive’s
services, the Company shall pay to the Executive an annual base salary of not less than $[SALARY] per annum, payable in equal periodic
installments according to the Company’s customary payroll practices, but no less frequently than monthly. The Executive’s
base salary shall be subject to review annually by the Compensation Committee and shall be subject to increase at the option and
sole discretion of the Compensation Committee.

 

    	 

    	 

    

 

b. Bonus. The Executive shall be
eligible to receive at the sole discretion of the Compensation Committee, an annual cash bonus of up to an additional [ %]
of the Executive’s base salary [provided, however, that for fiscal year 2013, the Executive shall receive an annual cash
bonus no less than Executive’s target bonus, which will be paid on the earlier of (i) the Closing Date and (ii) the date
such annual bonuses would otherwise be paid during the first calendar quarter of 2014.] . In addition, the Executive may be eligible
for additional bonuses at the option and sole discretion of the Compensation Committee based upon the achievement of certain pre-determined
performance milestones.

 

c. Benefits Generally.

 

		i.	In addition to the salary and cash bonus described above,
the Executive shall be entitled during the Employment Period to participate in such employee benefit plans and programs of the
Company, and shall be entitled to such other fringe benefits, as are from time to time made available by the Company generally
to employees of the level, position, tenure, salary, age, health and other qualifications of the Executive including, without
limitation, medical, dental and vision insurance coverage for the Executive and the Executive’s dependents, disability,
death benefit and life insurance and pension plans. [For all purposes, including eligibility, and vesting, the Executive
shall be credited for Executive’s prior service with Theraclone prior to the Closing.]

 

		ii.	[The Executive will be entitled to receive such equity
compensation awards as the Compensation Committee may grant to the Executive from time to time; subject to such terms and conditions
as the Compensation Committee may impose.]

 

		iii.	The Executive acknowledges and agrees that the Company
does not guarantee the adoption or continuance of any particular employee benefit plan and participation by the Executive in any
such plan or program shall be subject to the rules and regulations applicable thereto.

 

d. Vacation. The Executive shall
be entitled to twenty (20) days of vacation in each calendar year.

 

e. Expenses. During the Employment
Period, the Company shall reimburse the Executive in accordance with the practices in effect from time to time for other officers
or staff personnel of the Company for all reasonable and necessary business and travel expenses and other disbursements incurred
by the Executive for or on behalf of the Company in the performance of the Executive’s duties hereunder, upon presentation
by the Executive to the Company of appropriate supporting documentation. The Company shall reimburse approved expenses as soon
as practicable after submission, but in no event later than the last day of the tax year following the tax year in which the expense
was incurred. The amount of expenses eligible for reimbursement in one year will not affect the expenses eligible for reimbursement
in another year.

 

    	 

    	 

    

 

f. Perquisites. The Executive shall
be entitled to those perquisites as the Company shall make available from time to time to other executive officers of the Company,
which shall include, without limitation, the costs for the Executive’s use of a cellular telephone, personal digital assistant
and a laptop computer to the extent such equipment is used for business purposes.

 

5. Death; Disability. In the event
that the Executive dies or is incapacitated or disabled by accident, sickness or otherwise, so as to render the Executive mentally
or physically incapable of performing the services required to be performed by the Executive under this Agreement for a period
that would entitle the Executive to qualify for long-term disability benefits under the Company’s then-current long-term
disability insurance program or, in the absence of such a program, for a period of one hundred twenty (120) consecutive days or
longer (such condition being herein referred to as a “Disability”) then (i) in the case of the Executive’s
death, the Executive’s employment shall be deemed to terminate on the date of the Executive’s death and (ii) in the
case of a Disability, the Company, at its option, may terminate the employment of the Executive under this Agreement immediately
upon giving the Executive notice to that effect. The determination to terminate the Executive in the event of a Disability shall
be made by the Board or the Board’s designee. In the case of a Disability, until the Company shall have terminated the Executive’s
employment hereunder in accordance with the foregoing, the Executive shall be entitled to receive the compensation provided for
herein notwithstanding any such physical or mental disability.

 

6. Termination For Cause. The Company
may terminate the employment of the Executive hereunder at any time during the Employment Period for “cause” (such
termination being herein referred to as a “Termination for Cause”) by giving the Executive notice of such termination,
which termination shall be effective on the date of such notice or such later date as may be specified by the Company. For purposes
of this Agreement, “Cause” means (i) the Executive’s willful and substantial misconduct that can reasonably
be expected to affect materially and adversely the business or affairs of the Company, (ii) the Executive’s repeated neglect
of duties or failure to act that can reasonably be expected to affect materially and adversely the business or affairs of the Company
provided that neglect or failure to act has not been corrected, if capable of correction, within twenty (20) days after written
notice is provided to the Executive by the Company, (iii) the Executive’s material breach of any of the agreements contained
in Sections 11, 12, 13 or 14 hereof or of any of the Company’s policies, (iv) the commission by the Executive of any material
fraudulent act with respect to the business and affairs of the Company, (v) the Executive’s conviction of (or plea of nolo
contendere to) a crime constituting a felony, (vi) demonstrable gross negligence, or (vii) habitual insobriety or use of illegal
drugs by the Executive while performing the Executive’s duties under this Agreement.

 

7. Termination Without Cause. The
Company may terminate the employment of the Executive hereunder at any time without “cause” (such termination being
herein referred to as “Termination without Cause”) by giving the Executive notice of such termination, upon
the giving of which such termination shall take effect as of the date indicated in such notice.

 

    	 

    	 

    

 

8. Voluntary Termination by Executive.
Any termination of the employment of the Executive by the Executive otherwise than as a result of death or Disability or for Good
Reason (as defined below) shall be herein referred to as “Voluntary Termination”. A Voluntary Termination will
be deemed to be effective immediately upon such termination.

 

9. Termination by Executive for
Good Reason. Any termination of the employment of the Executive by the Executive for Good Reason shall be deemed to be
equivalent to a Termination without Cause. For purposes of this Agreement “Good Reason” means (i) any
material breach by the Company of any of its obligations under this Agreement (which shall include any material reduction in
the Executive’s base salary, (ii) any material reduction in the Executive’s duties, authority or
responsibilities, without the Executive’s consent, (iii) any assignment to the Executive of duties or responsibilities
materially inconsistent with the Executive’s position and duties, without the Executive’s consent, or (iv) the
Company’s determination to require the Executive’s principal place of work to be a location anywhere other than
within fifty (50) miles of the location of the Executive's principal place of work as of the Effective Date; provided,
however, that the Executive may not terminate the Executive’s employment for Good Reason unless the Executive first
provides the Company with written notice specifying the Good Reason within ninety (90) days after the first occurrence of an
event or condition that constitutes Good Reason, the Company fails to remedy or cure the event or condition that constitutes
Good Reason within thirty (30) days after it receives such written notice and the Executive must terminate the
Executive’s employment within thirty (30) days following expiration of such cure period.

 

10. Effect of Termination of Employment.

 

a. Voluntary Termination; Termination
For Cause. Upon the termination of the Executive’s employment as a result of the Executive’s Voluntary Termination
or a Termination for Cause, the Executive shall not have any further rights or claims against the Company under this Agreement
except the right to receive (i) the unpaid portion of the base salary provided for in Section 4(a) hereof, computed on a pro rata
basis to the date of termination, (ii) payment of the Executive’s accrued but unpaid amounts and extension of applicable
benefits in accordance with the terms of any incentive compensation, retirement, employee welfare or other employee benefit plans
or programs of the Company in which the Executive is then participating in accordance with the terms of such plans or programs,
and (iii) reimbursement for any expenses for which the Executive shall not have theretofore been reimbursed as provided in Section
4(e) hereof.

 

    	 

    	 

    

 

b. Termination Without Cause; Termination
for Good Reason. Upon the termination of the Executive’s employment as a result of a Termination without Cause or for
Good Reason, the Executive shall not have any further rights or claims against the Company under this Agreement except the right
to receive (i) the payments and other rights provided for in Section 10(a) hereof and (ii) severance benefits in the form of (A)
a continuation of the Executive’s base salary as in effect immediately prior to such termination (but without regard to any
reduction in base salary that was the event of Good Reason) for a period of 12 months following the effective date of such termination;
and (B) to the extent that the Executive has elected and is continuing to receive COBRA continuation coverage under the Company’s
group health plan in accordance with Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”),
the Company shall reduce the COBRA premiums that the Executive is required to pay during the first twelve (12) months following
the Executive’s termination of employment to that the Company charges to its active employees for the same level of group
health coverage; provided, however, that the severance benefits described in clause (b)(ii) herein shall be provided in consideration
for, and only after the Executive executes a General Release (which shall be provided on or about the date of termination) containing
terms reasonably satisfactory to the Company within the time specified therein, but in no event later than fifty (50) days following
the Executive’s termination of employment. Subject to Section 24 hereof, if the Executive timely executes such General Release
and the applicable revocation period with respect to such General Release lapses, the Executive shall receive the first two (2)
months of Executive’s salary continuation as provided in clause (ii) herein sixty (60) days after the Executive’s termination
of employment and the remaining payments in accordance with the Company’s payroll practices. If the Executive does not timely
execute the General Release or if the Executive revokes the General Release within the applicable revocation period prescribed
by law, the Executive shall not be entitled to receive any severance benefits and the Executive will be required to pay one hundred
two percent (102%) of the applicable premium (as defined in Code Section 4980B) for any COBRA continuation coverage elected by
the Executive.

 

c. Death and Disability. Upon the
termination of the Executive’s employment as a result of death or Disability, neither the Executive nor the Executive’s
beneficiaries or estate shall have any further rights or claims against the Company under this Agreement except the right to receive
the payments and other rights provided for in Sections 5 and 10(a) hereof.

 

d. 280G Excise Tax. If (1) any amounts
payable to Executive under this Agreement or otherwise are characterized as excess parachute payments pursuant to Section 4999
of the Internal Revenue Code of 1986, as amended (the “Code”), and (2) Executive thereby would be subject to any United
States federal excise tax due to that characterization, then Executive’s termination benefits hereunder will be payable either
in full or in a lesser amount, whichever would result, after taking into account the applicable federal, state and local income
taxes and the excise tax imposed by Section 4999, in Executive’s receipt on an after-tax basis of the greatest amount of
termination and other benefits. The determination of any reduction required pursuant to this section (including the determination
as to which specific payments shall be reduced) shall be made by a nationally recognized accounting firm doing business in the
United States which otherwise does not perform services for the Company (which will be chosen by the mutual agreement of Executive
and the Company, such services to be paid by the Company), and such determination shall be conclusive and binding upon the Company
or any related corporation for all purposes. If required, the payments and benefits under this Agreement shall be reduced in the
following order: (A) a pro rata reduction of (i) cash payments that are subject to Section 409A as deferred compensation and (ii)
cash payments not subject to Section 409A; (B) a pro rata reduction of (i) employee benefits that are subject to Section 409A as
deferred compensation and (ii) employee benefits not subject to Section 409A; and (C) a pro rata cancellation of (i) accelerated
vesting of stock and other equity-based awards that are subject to Section 409A as deferred compensation and (ii) stock and other
equity-based awards not subject to Section 409A. In the event that acceleration of vesting of stock and other equity-based award
compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of Executive’s
stock and other equity-based awards unless Executive elects in writing a different order for cancellation.

 

    	 

    	 

    

 

11. Disclosure of Confidential Information.
The Executive shall not, directly or indirectly, at any time during or after the Employment Period, disclose to any person, firm,
corporation or other business entity, except as required by law, or use or copy for any purpose except in the good faith performance
of the Executive’s duties to the Company, any Confidential Information (as herein defined). For purposes of this Agreement,
“Confidential Information” means all trade secrets and all other non-public information of a business, financial,
marketing, technical or other nature regardless of the form in which it is maintained (i.e.,
whether electronically, on computer disk, in a written document, photograph, or audio or video recording) pertaining to the
Company or any subsidiary, including information of others that the Company or any subsidiary has agreed to keep confidential,
including any such information developed by the Executive during the course of the Executive’s employment with the Company;
provided, however, that Confidential Information shall not include any information that has entered or enters the public domain
(other than through breach of the Executive’s obligations under this Agreement) or which the Executive is required to disclose
by law or legal process. Upon the Company’s request at any time and upon termination of the Executive’s employment,
the Executive shall immediately deliver to the Company all materials, including all copies of materials, in the Executive’s
possession and/or control which contain Confidential Information, and shall not make or retain copies in any form of Confidential
Information. [For purposes of this Section 11, Confidential Information shall include Confidential Information of Theraclone
that the Executive had access to pursuant to the Executive’s employment
with Theraclone prior to the Effective Date.]

 

12. Restrictive Covenants. The Executive
hereby acknowledges and recognizes that, during the Executive’s employment with [PharmAthene] [Theraclone]
prior to the Effective Date and during the Employment Period, the Executive has been and shall be privy to trade secrets and Confidential
Information and has developed and will develop relationships with the Company’s customers and their representatives, business partners, referral sources, other third parties critical to the Company’s
business (“Key Relationships”). Accordingly, in consideration of the benefits to be received by the Executive hereunder,
[FOR KARP – except as otherwise provided under Maryland law and the Maryland rules of Professional Responsibility applicable
to lawyers], the Executive agrees to the following Restrictive Covenants:

 

    	 

    	 

    

 

a. Non-Competition. The Executive
shall not, from and after the date hereof, throughout the Employment Period, and for a period of twelve (12) months following the
termination of the Employment Period (the “Restricted Period”) (i) directly or indirectly engage in the development,
production, marketing or sale of products that compete (or, upon commercialization, would compete) with products of the Company
being developed (so long as such development has not been abandoned), marketed or sold at the time of the termination of the Employment
Period (such business or activity being herein referred to as a “Competing Business”) whether such engagement
shall be as an officer, director, owner, executive, manager, employee, partner, affiliate or other participant in any Competing
Business, or (ii) assist others in engaging in any Competing Business in the manner described in the foregoing clause (i).

 

b. Dealings with customers and Key Relationships.

 

i.            During
the Restricted Period, the Executive shall not, on behalf of the Executive,
or in any capacity whatsoever for any entity or person, other than the Company, and without the express written permission of the
Company, directly or indirectly, contact, solicit, market to, sell to, consult with, or perform any services whatsoever for and/or
in conjunction with any customer or Key Relationship with whom the Executive has had any contact during the Executive’s employment
with the Company, with respect to any Competing Business, and further, the Executive shall not encourage, induce, or urge any customer
or Key Relationship to cease doing business with the Company. If during this period a customer or Key Relationship contacts the
Executive to perform services through a means other than through the Company, the Executive agrees to promptly notify the Company.

 

ii.         The
Executive understands that this prohibition against indirectly contacting, soliciting, marketing to, or selling to any customer
and Key Relationship on behalf of the Executive or any entity or person other than the Company means that the Executive shall not
provide information to any entity or person regarding any customer or Key Relationship; introduce any entity or person to any customer
or Key Relationship; advise, suggest, or encourage any customer or Key Relationship that it should do business with any entity
or person other than the Company, participate in the supervision and management of any of the accounts relating to any customer
or Key Relationship; participate in the consultation of any customer or Key Relationship; participate in the development or implementation
of any strategies and decisions affecting any customer or Key Relationship; or in any way, state or imply to any customer or Key
Relationship that doing business with any other entity or person during the restrictive period will inure to the Executive’s
present or future benefit.

 

iii.         The
foregoing restrictions will be limited to those customers and Key relationships with whom the Executive had any contact during
the two (2) year period preceding the Executive’s termination of employment with the Company, including any telephonic, electronic,
written, or in-person solicitations of, meetings with, or sales involving the customer or Key Relationship; the performance by
the Executive of any services for and/or with and/or involving the customer or Key Relationship; any participation by the Executive
in the supervision and management of any of the accounts relating to the
customer or Key Relationship; consultation with any customer or Key Relationship; the development or implementation of any strategy
and/or decision affecting and/or involving any customer or Key Relationship; or access to any Confidential Information relating
to any customer or Key Relationship.

 

    	 

    	 

    

 

c.           Non-Solicitation
of Employees. During the Restricted Period, the Executive shall not, directly or indirectly, on behalf of the Executive or
for any other entity or person, hire, entice, induce, encourage, urge, or solicit, or attempt to hire, entice, induce, encourage,
urge, or solicit any employee of the Company or any subsidiary of the Company to leave the Company's or subsidiary’s employ
or to cause any employee of the Company or any subsidiary or any person who had been employed by the Company or any subsidiary
at any time during the preceding twelve (12) month period, to leave the Company’s employ or to become employed by any other
person or entity that, in whole or in part, is a Competing Business.

 

d.           Limitation
of Restrictive Covenants. The Restrictive Covenants set forth in this Section 12 apply only to the extent that the Executive’s
activities relate directly or indirectly to a Competing Business. [For purposes of the Restrictive Covenants, references to the
“Company” shall be deemed to include Theraclone prior to the Effective Date.]

 

13. Non-Disparagement. The Executive
shall not engage in conduct, through word, act, gesture or other means, or disclose any information to the public or any third
party which (i) directly or indirectly discredits or disparages in whole or in part the Company or Theraclone, or the respective
subsidiaries, divisions, affiliates and/or successors of the Company or Theraclone as well as the products and the respective officers,
directors, stockholders and employees of each of them; (ii) is detrimental to the reputation, character or standing of these entities,
their products or any of their respective officers, directors, stockholders and/or employees; or (iii) which generally reflects
negatively on the management decisions, strategy or decision-making of these entities. Factual statements made in legal actions,
legal proceedings, or government investigative proceedings that are protected by a qualified privilege or immunity are not intended
to be construed as disparagement.

 

14. Company Right to Inventions.
The Executive hereby acknowledges that during the course of the Executive’s employment the Executive may be expected to apply
intellectual efforts to develop and/or improve the Company's products and to conceive new ideas and products that will benefit
the Company in its business. All Inventions and Works which, during the Executive’s employment with the Company or previously
as a [PharmAthene employee] [Theraclone employee prior to the Effective Date] (whether or not during usual working hours) and for
a period of one year thereafter, the Executive designs, creates or develops or designed, created or developed, solely or in conjunction
with others, in the course of the performance of the Executive’s duties or which relate to the business of the Company [and/or
Theraclone], are, together with all rights therein, acknowledged to be made or conceived for the exclusive benefit of the Company,
and will become the Company’s Intellectual Property Rights. The Executive agrees to immediately notify the Company upon the
design, creation or development of all Inventions and Works.

 

    	 

    	 

    

 

All Works shall be deemed “Works Made
For Hire,” as that term is used and understood within the Copyright Act of 1976, as amended. To the extent any Works are
determined not to be "Works Made For Hire," and to the extent that title to or ownership of any Invention or Work and
all other rights therein are not otherwise vested exclusively in the Company, the Executive shall, at any time, without further
consideration, but at the Company's expense, assign and transfer to the Company Executive’s entire right, title and interest
(including copyrights and patents) in and to all such Inventions and Works.

 

The Executive agrees to cooperate fully
with the Company, its successors, assigns, or designees in protecting the Intellectual Property Rights. At the Company’s
request the Executive will execute and deliver to the Company all documents or instruments which may be necessary to secure and
perfect the Company's title to and ownership of Inventions and Works, including, but not limited to, applications for letters patent
(and extensions, continuations and reissues), applications for copyrights, and documents or instruments of assignment or transfer.
The Executive further agrees to assist in the maintenance of those Intellectual Property Rights and in the prosecution or other
legal or administrative proceedings involving same. The Executive agrees that Executive’s obligation to execute any and all
such instruments and documents and to render such cooperation shall continue after the termination of the Executive’s employment.
It is understood that all expenses of applying for and obtaining the Intellectual Property Rights shall be borne by the Company.
Further, the Company shall reimburse the Executive for the time spent and reasonable travel and other out-of-pocket expenses that
he incurs in connection with any steps that he take pursuant to the provisions of this Section, provided such time was spent and
such expenses were incurred at the prior written request and/or with the prior written approval of the Company.

 

15. Severability and Enforceability.
It is the desire and intent of the parties hereto that the provisions of this Agreement be enforceable in each jurisdiction in
which enforcement is sought to the fullest extent permissible. This Agreement is divisible and separable, so that if any provision
shall be held to be invalid, unlawful, or unenforceable, such holding shall not impair the remaining provisions. If any provision
is held to too broad or unreasonable in duration, scope, or character of restriction to be enforced, such provision shall be modified
to the extent necessary in order to legally enforce such provision to the fullest extent permitted by law. Both the Company and
the Executive expressly authorize any court of competent jurisdiction to enforce any such provision to the fullest extent permitted
by law.

 

    	 

    	 

    

 

16. Remedies; Survival.

 

a. Injunctive Relief. The Executive
acknowledges and understands that the provisions of the covenants contained in Sections 11, 12, 13 and 14 hereof, the violation
of which cannot be accurately compensated for in damages by an action at law, are of crucial importance to the Company, and that
the breach or threatened breach of the provisions of this Agreement would cause the Company irreparable harm. In the event of a
breach or threatened breach by the Executive of the provisions of Sections 11, 12, 13 or 14 hereof, the Company shall be entitled
to an injunction restraining the Executive from such breach, and the Executive hereby consents to the issuance of an injunction,
without the obligation of the Company to post any bond. Nothing herein contained shall be construed as prohibiting the Company
from pursuing any other remedies available for any breach or threatened breach of this Agreement.

 

b. Extension of Restricted Period. The
Restricted Period set forth in Section 12 shall be extended by a period equal to the time period during which the Executive is
in breach of any of such provisions.

c.Attorneys’ Fees and Costs.
In a dispute arising out of or related to this Agreement or the Executive’s employment, the prevailing party shall have the
right to collect from the other party its reasonable attorney fees and costs and necessary expenditures.

 

d. Survival. Notwithstanding anything
contained in this Agreement to the contrary, the provisions of this Agreement shall survive the termination of the Executive’s
employment until, by their terms, such provisions are no longer operative.

 

17. Notices. Notices and other communications
hereunder shall be in writing and shall be delivered personally or sent by air courier or first class certified or registered mail,
return receipt requested and postage prepaid, addressed as follows:

if to the Company:

 

______________________________

 

______________________________

 

______________________________

 

______________________________

 

with a copy to:

 

______________________________

 

______________________________

 

______________________________

 

______________________________

 

    	 

    	 

    

 

if to the Executive to:

 

______________________________

 

______________________________

 

______________________________

 

______________________________

 

with a copy to:

 

______________________________

 

______________________________

 

______________________________

 

______________________________

 

All notices and other communications given
to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of delivery,
if personally delivered; on the business day after the date when sent, if sent by air courier; and on the third business day after
the date when sent, if sent by mail, in each case addressed to such party as provided in this Section 17 or in accordance with
the latest unrevoked direction from such party.

 

18. Binding Agreement; Benefit. The
provisions of this Agreement shall be binding upon, and shall inure to the benefit of, the respective heirs, legal representatives
and successors of the parties hereto.

 

19. Governing Law; Jurisdiction. 
This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the state of [Maryland]
[Washington] applicable to a contract made and to be performed therein. Any action to enforce any of the provisions of this Agreement
shall be brought in a court of the state of [Maryland] [Washington] or
in Federal court located within that State. The parties consent to the jurisdiction of such courts and to the service of process
in any manner provided by [Maryland] [Washington] law. Each party irrevocably waives any objection which it may now or hereafter
have to the laying of the venue of any such suit, action or proceeding brought in such court and any claim that such suit, action
or proceeding brought in such court has been brought in an inconvenient forum and agrees that service of process in accordance
with the foregoing shall be deemed in every respect effective and valid personal service of process upon such party.

 

    	 

    	 

    

 

20. Waiver of Breach. The waiver
by either party of a breach of any provision of this Agreement by the other party must be in writing and shall not operate or be
construed as a waiver of any subsequent breach by such other party.

 

21. Entire Agreement; Amendments.
This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes upon
its effectiveness all prior agreements or understandings among the parties with respect thereof[, including without limitation,
the Prior Agreement]. This Agreement may be amended only by an agreement in writing signed by the parties hereto.

 

22. Headings. The section headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement.

 

23. Severability.  Any provision
of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the
extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

24. 409A Compliance. If the Executive
is a “specified employee” (as determined in accordance with Treasury Regulation Section 1.409A-1(i) or any written
Company policy implementing such regulation) at the time of the Executive’s termination of employment, then the Executive’s
severance payments that are otherwise payable during the first six-month period following the Executive’s termination of
employment (to the extent that such severance payments constitute nonqualified deferred compensation within the meaning of Section
409A of the Code and the regulations promulgated thereunder) shall be deferred until the date that is six (6) months after the
Executive’s termination of employment (or, if earlier, upon the Executive’s death). Each severance payment that is
due hereunder shall be treated as a separate payment for purposes of Section 409A of the Code. Each severance payment that satisfies
the requirements of the “short-term deferral” rule set forth in Section 409A of the Code is not intended to constitute
deferred compensation. Moreover, any severance payment that does not exceed the Section 409A limit as set forth in Section 409A-1(b)(9)(iii)(A)(1)
of the Code is not intended to constitute deferred compensation. All severance payments shall be completed by, and no further severance
benefits shall be payable after, December 31 of the second taxable year following the year in which the Executive’s termination
of employment occurs. This Agreement shall be interpreted to comply with, or otherwise be exempt from, the requirements of Section
409A. Accordingly, references to termination of employment hereunder shall be interpreted to mean “separation from service”
as defined in regulations under Section 409A of the Code.

 

25. Executive’s Acknowledgement.
The Executive acknowledges (a) that the Executive has had the opportunity to consult with independent counsel of the Executive’s
own choice concerning this Agreement and (b) that the Executive has read and understands the Agreement, is fully aware of its legal
effect and has entered into it freely based on the Executive’s own judgment.

 

    	 

    	 

    

 

26. Assignment. The Executive understands
and agrees that the Company may assign this Agreement to any entity or person that purchases substantially all or part of the
Company’s assets or purchases any subsidiary, affiliate, or division of the Company for which the Executive has performed
any services pursuant to this Agreement, and the Executive hereby consents to any such assignment. The Executive further understands
and agrees that he may not assign this Agreement.

 

27. Indemnification. The Company shall, to the maximum extent permitted
by law, indemnify and hold the Executive harmless against, and shall purchase director and officer indemnity insurance on behalf
of the Executive for, expenses, including reasonable attorneys’ fees (the attorney to be selected by the Executive), judgments, fines, settlements and other amounts actually and reasonably incurred in connection with
any proceeding or claim (or threatened proceeding or claim) arising by reason of the Executive’s employment by the Company.
The Company shall advance to the Executive any expense incurred in defending
any such proceeding or claim (or threatened proceeding or claim) to the maximum extent permitted by law. The above indemnification
provision shall be in addition to, and shall not be interpreted to limit or reduce, any other indemnification obligations of the
Company to the Executive, whether under contract, the Company’s certificate of incorporation, the Company’s bylaws,
or under law or otherwise.

 

28. Resignation of All Other Positions.
Unless otherwise agreed to in writing by the Executive and the Company at the time of Termination, upon Termination the Executive
shall be deemed to resign (i) if a member, from the Board and the board of directors of any Affiliate and any other board to which
the Executive has been appointed or nominated by or on behalf of the Company or an Affiliate, (ii) from each position with the
Company and any Affiliate, including as an officer of the Company or an Affiliate, and (iii) as a fiduciary of any employee benefit
plan of the Company and any Affiliate.

 

29. Litigation and Regulatory Cooperation.
During and after the Executive’s employment, the Executive shall reasonably cooperate with the Company in the defense or
prosecution of any claims or actions then in existence or which may be brought in the future against or on behalf of the Company
which relate to events or occurrences that transpired while the Executive was employed by the Company. The Executive’s cooperation
in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare
for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s
employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal,
state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while
the Executive was employed by the Company. The Company shall provide the Executive with compensation on an hourly basis at a rate
equivalent to the hourly rate of the Executive’s last annual Base Salary calculated using a forty (40) hour week over fifty-two
(52) weeks for requested litigation and regulatory cooperation and occurs after the Executive's termination of employment, and
reimburse the Executive for all costs and expenses incurred in connection with the Executive's performance under this Section 29,
including, but not limited to, reasonable attorneys’ fees and costs.

 

    	 

    	 

    

 

30. Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall for all purposes constitute one agreement which is binding on
all of the parties hereto.

 

IN WITNESS WHEREOF, the parties have duly
executed this Agreement as of the date first above written.

 

	EXECUTIVE	 
	 	 
	 	 
	[NAME]	 
	 	 
	PHARMATHENE, INC.	 
	 	 
	 	 
	By:	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]